CRL
Charles River Laboratories International IncHealth Careinsider_universeEverything we've seen
- ?Sep 14, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- !Sep 14, 3:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- ?Sep 14, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- !Sep 14, 3:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- ?Sep 14, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- !Sep 14, 2:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- ?Sep 14, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- !Sep 14, 2:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- ?Sep 14, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- !Sep 14, 11:21 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- ?Sep 14, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- !Sep 14, 11:21 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- ?Sep 14, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- !Sep 14, 10:21 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high with no news headlines to explain the move, suggesting the drop is macro/sector-driven rather than company-specific. Health Care (XLV) is underperforming SPY on both 5d and 30d bases, implying CRL is partly caught in sector-wide selling pressure. Options flow is muted and balanced (low z-scores on both calls and puts, P/C of 0.40), offering no unusual directional signal. However, insider activity is a meaningful negative signal — a Director sold over $10M in shares and the CEO received shares at $0 cost, while a senior VP also sold, with no offsetting insider purchases to suggest conviction in the dip.
- ?Sep 14, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- !Sep 14, 10:21 AMsignalseverity 0.12
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL (Charles River Laboratories) is down 11.5% from its 30-day high, which is below the +1 threshold of >=15%. No hard vetoes apply: earnings are 50 days away (clean runway, +1), and no fundamental deterioration is visible in recent filings (metrics are empty, no red flags). Signal scoring: +1 for no earnings within 30 days; +1 for sector underperformance (Health Care ranks 4/11, lagging SPY on both 5d and 30d basis); -1 for insider sales that are large and clustered (CEO and Director FOSTER sold ~$10M in a coordinated fashion on 8/25); -1 for elevated 10Y yield at 4.95% (above 4.5% structural headwind); -1 for the broad market in risk-off mode today (VIX elevated, SPY/QQQ down, UUP up). Net score: -1, which per the framework does not support a buy. Options flow is modestly bullish (P/C 0.40, call-dominated) but z-scores are near zero, not "unusual." The base rate anchor of ~57% is dragged down by the net negative signal score to just below the 0.50 threshold.
- ?Sep 11, 10:20 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 1.59% today, a modest but real move suggesting some directional flow. No headlines are present to explain the move, which is common — the absence of news does not negate the momentum signal. With 325 minutes remaining (well over half the session), there is ample time for continuation if buying pressure persists. However, the macro context is a mild headwind: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above its 24-month trend, which points to elevated rate expectations broadly. CRL (Charles River Laboratories) is a life sciences services company — not classically rate-sensitive, but elevated inflation expectations can compress biotech/pharma R&D budgets over time and create sector-level risk-off sentiment. The move is below the 2% threshold where momentum signals become more compelling, keeping confidence modest. On balance, with ample time remaining, no reversal pattern evident, and the system's asymmetric payoff (tight stop vs. fixed target), a slight lean toward continuation is warranted, but conviction is low.
- !Sep 11, 10:20 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 1.59% today, a modest but real move suggesting some directional flow. No headlines are present to explain the move, which is common — the absence of news does not negate the momentum signal. With 325 minutes remaining (well over half the session), there is ample time for continuation if buying pressure persists. However, the macro context is a mild headwind: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above its 24-month trend, which points to elevated rate expectations broadly. CRL (Charles River Laboratories) is a life sciences services company — not classically rate-sensitive, but elevated inflation expectations can compress biotech/pharma R&D budgets over time and create sector-level risk-off sentiment. The move is below the 2% threshold where momentum signals become more compelling, keeping confidence modest. On balance, with ample time remaining, no reversal pattern evident, and the system's asymmetric payoff (tight stop vs. fixed target), a slight lean toward continuation is warranted, but conviction is low.
- ?Sep 10, 1:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down ~2.04% today with no attributed headline, suggesting institutional flow rather than retail-driven news reaction. The move is at the lower threshold of meaningful conviction. Macro context shows the 5Y5Y forward inflation rate running 1.6σ above trend, which pressures rate-sensitive and growth-oriented sectors — CRL as a life sciences CDMO/CRO carries some rate sensitivity in valuation, modestly supportive of continued pressure. However, with 125 minutes remaining, there is adequate time for continuation, but also risk of mean-reversion into the close if the selling was front-loaded this morning. No reversals or fade patterns are indicated in the data, and absence of news does not disqualify the move. The setup is borderline — no strong catalyst to extend, but macro backdrop leans slightly bearish for the name and the move itself implies real sell-side flow. Assigning 0.50 as a neutral-to-slight continuation read, consistent with taking the position given bounded downside via the stop framework.
- !Sep 10, 1:40 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down ~2.04% today with no attributed headline, suggesting institutional flow rather than retail-driven news reaction. The move is at the lower threshold of meaningful conviction. Macro context shows the 5Y5Y forward inflation rate running 1.6σ above trend, which pressures rate-sensitive and growth-oriented sectors — CRL as a life sciences CDMO/CRO carries some rate sensitivity in valuation, modestly supportive of continued pressure. However, with 125 minutes remaining, there is adequate time for continuation, but also risk of mean-reversion into the close if the selling was front-loaded this morning. No reversals or fade patterns are indicated in the data, and absence of news does not disqualify the move. The setup is borderline — no strong catalyst to extend, but macro backdrop leans slightly bearish for the name and the move itself implies real sell-side flow. Assigning 0.50 as a neutral-to-slight continuation read, consistent with taking the position given bounded downside via the stop framework.
- ?Sep 10, 11:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 1.85% today, which is a moderate but not dramatic move. No headlines are present to explain the decline, meaning this is likely technical or sector-driven flow. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend, which broadly pressures rate-sensitive sectors — CRL as a contract research organization is not particularly rate-sensitive in the classic sense, so this macro factor is largely neutral to mildly negative. With 240 minutes (4 hours) remaining until the forced close, there is ample time for the move to extend, but also for a mean-reversion bounce if the selling was front-loaded in the session. The absence of a news catalyst makes it harder to assign high continuation probability — without a fundamental driver, intraday momentum at this magnitude (~2%) can stall or reverse. No reversal signal is evident either, so there is no strong reason to call a fade. On balance, the setup is borderline: modest momentum, neutral macro, no news, plenty of time remaining. Assigning 0.50 — the move may continue but conviction is low.
- !Sep 10, 11:45 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 1.85% today, which is a moderate but not dramatic move. No headlines are present to explain the decline, meaning this is likely technical or sector-driven flow. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend, which broadly pressures rate-sensitive sectors — CRL as a contract research organization is not particularly rate-sensitive in the classic sense, so this macro factor is largely neutral to mildly negative. With 240 minutes (4 hours) remaining until the forced close, there is ample time for the move to extend, but also for a mean-reversion bounce if the selling was front-loaded in the session. The absence of a news catalyst makes it harder to assign high continuation probability — without a fundamental driver, intraday momentum at this magnitude (~2%) can stall or reverse. No reversal signal is evident either, so there is no strong reason to call a fade. On balance, the setup is borderline: modest momentum, neutral macro, no news, plenty of time remaining. Assigning 0.50 — the move may continue but conviction is low.
- ?Sep 8, 12:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 1.62% today with no attributable headline catalyst, suggesting the move may be macro or sector-driven rather than company-specific. The macro context shows the 5-year forward inflation rate running 1.7σ above its 24-month trend, which is mildly negative for rate-sensitive and growth-oriented names like CRL (a contract research organization with valuation sensitivity to discount rates). However, a 1.62% move is below the 2-5% threshold that would constitute strong directional evidence on its own. With 225 minutes remaining there is ample time for continuation or reversal. No reversal signals are present, but equally no strong continuation catalysts are evident. The elevated inflation expectations could provide modest continued pressure on rate-sensitive equities into the close. On balance, this is a borderline setup — the macro tilt is slightly negative for the name, the move is real but modest, and time remaining is substantial. Assigning the minimum threshold probability given no active reason to fade but no strong conviction driver either.
- !Sep 8, 12:01 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 1.62% today with no attributable headline catalyst, suggesting the move may be macro or sector-driven rather than company-specific. The macro context shows the 5-year forward inflation rate running 1.7σ above its 24-month trend, which is mildly negative for rate-sensitive and growth-oriented names like CRL (a contract research organization with valuation sensitivity to discount rates). However, a 1.62% move is below the 2-5% threshold that would constitute strong directional evidence on its own. With 225 minutes remaining there is ample time for continuation or reversal. No reversal signals are present, but equally no strong continuation catalysts are evident. The elevated inflation expectations could provide modest continued pressure on rate-sensitive equities into the close. On balance, this is a borderline setup — the macro tilt is slightly negative for the name, the move is real but modest, and time remaining is substantial. Assigning the minimum threshold probability given no active reason to fade but no strong conviction driver either.
- ?Sep 8, 11:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 2.27% today with no attributable headline, suggesting this is likely flow-driven selling rather than a news-catalyst event. The move is meaningful in magnitude — real size is involved. With 285 minutes remaining (nearly a full trading day remaining until the 3:45 cutoff), there is ample time for continuation to develop. The macro context shows 5-year forward inflation expectations running 1.7σ above trend, which creates a moderately unfavorable backdrop for rate-sensitive names; CRL as a contract research organization has some rate/growth sensitivity given its capital-intensive, long-duration revenue profile. The absence of news cuts both ways — no catalyst to fade against, but also no clear narrative to sustain momentum beyond pure technical/flow pressure. With no reversal signals noted and time remaining substantial, the default lean per system rules is slight continuation. Assigning 0.52 — modest conviction for downside continuation, reflecting uncertainty from lack of news but respecting the magnitude of the move and available time.
- !Sep 8, 11:01 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 2.27% today with no attributable headline, suggesting this is likely flow-driven selling rather than a news-catalyst event. The move is meaningful in magnitude — real size is involved. With 285 minutes remaining (nearly a full trading day remaining until the 3:45 cutoff), there is ample time for continuation to develop. The macro context shows 5-year forward inflation expectations running 1.7σ above trend, which creates a moderately unfavorable backdrop for rate-sensitive names; CRL as a contract research organization has some rate/growth sensitivity given its capital-intensive, long-duration revenue profile. The absence of news cuts both ways — no catalyst to fade against, but also no clear narrative to sustain momentum beyond pure technical/flow pressure. With no reversal signals noted and time remaining substantial, the default lean per system rules is slight continuation. Assigning 0.52 — modest conviction for downside continuation, reflecting uncertainty from lack of news but respecting the magnitude of the move and available time.
- ?Sep 2, 9:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.38% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop. The move is meaningful but not extreme. Macro context shows 5Y5Y forward inflation (T5YIFR) running 1.7σ above trend, which is mildly rate-hawkish — CRL as a contract research organization is not highly rate-sensitive, so this macro factor is largely neutral to the setup. With 350 minutes remaining (well before the 3:45 cutoff), there is ample time for continuation. No reversal signal is evident from the data provided. The absence of news is not a disqualifier per the framework. The setup reads as ordinary momentum with no strong fade catalyst — CRL's move likely reflects real conviction buying that has not yet exhausted itself, but without volume confirmation data or a clear catalyst, conviction is moderate. Assigning a modest continuation probability above the 0.5 threshold to capture the asymmetric risk/reward of the bounded stop/target structure.
- !Sep 2, 9:56 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 2.38% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop. The move is meaningful but not extreme. Macro context shows 5Y5Y forward inflation (T5YIFR) running 1.7σ above trend, which is mildly rate-hawkish — CRL as a contract research organization is not highly rate-sensitive, so this macro factor is largely neutral to the setup. With 350 minutes remaining (well before the 3:45 cutoff), there is ample time for continuation. No reversal signal is evident from the data provided. The absence of news is not a disqualifier per the framework. The setup reads as ordinary momentum with no strong fade catalyst — CRL's move likely reflects real conviction buying that has not yet exhausted itself, but without volume confirmation data or a clear catalyst, conviction is moderate. Assigning a modest continuation probability above the 0.5 threshold to capture the asymmetric risk/reward of the bounded stop/target structure.
- ?Aug 28, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 2.03% today with no attributable headline catalyst visible. The move is meaningful in magnitude — real selling flow has occurred. With 330 minutes remaining (roughly the full afternoon session), there is ample time for continuation if sellers maintain pressure. The macro context (elevated mortgage rates) is not directly relevant to CRL (Charles River Laboratories — a contract research organization in the biopharma/life sciences space), so no sector-level tailwind or headwind from FRED data applies here. Absence of a news catalyst does not disqualify the momentum read. The setup is ordinary mid-session downside drift: no strong reversal signal, no sector counter-pressure, and enough time remaining for the move to extend. Probability is held at the lower end of the continuation band (0.52) because: (1) no confirming catalyst exists to sustain institutional conviction, (2) a 2% intraday drop without news can attract mean-reversion buyers in the afternoon, and (3) the macro read is neutral-to-irrelevant for this ticker. A borderline continuation call — lean down, but modest confidence.
- !Aug 28, 10:15 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 2.03% today with no attributable headline catalyst visible. The move is meaningful in magnitude — real selling flow has occurred. With 330 minutes remaining (roughly the full afternoon session), there is ample time for continuation if sellers maintain pressure. The macro context (elevated mortgage rates) is not directly relevant to CRL (Charles River Laboratories — a contract research organization in the biopharma/life sciences space), so no sector-level tailwind or headwind from FRED data applies here. Absence of a news catalyst does not disqualify the momentum read. The setup is ordinary mid-session downside drift: no strong reversal signal, no sector counter-pressure, and enough time remaining for the move to extend. Probability is held at the lower end of the continuation band (0.52) because: (1) no confirming catalyst exists to sustain institutional conviction, (2) a 2% intraday drop without news can attract mean-reversion buyers in the afternoon, and (3) the macro read is neutral-to-irrelevant for this ticker. A borderline continuation call — lean down, but modest confidence.
- ?Aug 27, 12:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.30% today with no attributable headline, suggesting the move is driven by institutional flow or sector rotation rather than a news catalyst. With 210 minutes remaining (roughly 3.5 hours), there is ample time for continuation into the close. The macro context (elevated mortgage rates at 1.8σ above trend) is a mild headwind for rate-sensitive sectors like homebuilders and REITs, but CRL (Charles River Laboratories) operates in contract research/life sciences — not a sector directly reactive to mortgage rates — so the macro read is largely neutral here. Absence of news does not disqualify the move; a 2.3% move reflects real institutional conviction. No reversal signals are present. The setup is ordinary momentum with no strong reason to fade: probability sits modestly above 0.5 reflecting the clean directional move and ample time remaining, tempered by lack of a clear catalyst and no volume confirmation data available.
- !Aug 27, 12:15 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 2.30% today with no attributable headline, suggesting the move is driven by institutional flow or sector rotation rather than a news catalyst. With 210 minutes remaining (roughly 3.5 hours), there is ample time for continuation into the close. The macro context (elevated mortgage rates at 1.8σ above trend) is a mild headwind for rate-sensitive sectors like homebuilders and REITs, but CRL (Charles River Laboratories) operates in contract research/life sciences — not a sector directly reactive to mortgage rates — so the macro read is largely neutral here. Absence of news does not disqualify the move; a 2.3% move reflects real institutional conviction. No reversal signals are present. The setup is ordinary momentum with no strong reason to fade: probability sits modestly above 0.5 reflecting the clean directional move and ample time remaining, tempered by lack of a clear catalyst and no volume confirmation data available.
- ?Aug 27, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.25% today with no attributable headline, suggesting this is flow-driven rather than news-driven — someone with size initiated or added. The move is meaningful but not extreme, leaving room for continuation toward the +3% target. With 315 minutes remaining (roughly 5+ hours), there is ample time for the move to extend. The macro context (T5YIFR at 1.6σ above trend) signals elevated inflation expectations, which is modestly negative for rate-sensitive sectors, but CRL (Charles River Laboratories) is a life sciences/CRO name with limited direct rate sensitivity — this macro signal is not a strong headwind here. No reversal signals are evident from the data provided. The absence of news is neutral per the framework. The setup is ordinary momentum with no strong reason to fade — probability lands in the 0.5–0.65 range reflecting a modest lean toward continuation.
- !Aug 27, 10:30 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 2.25% today with no attributable headline, suggesting this is flow-driven rather than news-driven — someone with size initiated or added. The move is meaningful but not extreme, leaving room for continuation toward the +3% target. With 315 minutes remaining (roughly 5+ hours), there is ample time for the move to extend. The macro context (T5YIFR at 1.6σ above trend) signals elevated inflation expectations, which is modestly negative for rate-sensitive sectors, but CRL (Charles River Laboratories) is a life sciences/CRO name with limited direct rate sensitivity — this macro signal is not a strong headwind here. No reversal signals are evident from the data provided. The absence of news is neutral per the framework. The setup is ordinary momentum with no strong reason to fade — probability lands in the 0.5–0.65 range reflecting a modest lean toward continuation.
- ?Aug 5, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-07-09 through 2026-08-04, CRL spent 19 sessions consolidating in a tight $218.70–$240.43 price band on routine volume averaging roughly 800K shares/day — a classic low-volume price cluster in 2-D PV space. Today, 2026-08-05, the path launches decisively above that cluster: the close of $260.72 (+11.36%) is well clear of even the prior high of $240.43 (2026-07-28), accompanied by volume of 1.6M — a z-score of 4.00 versus the 20-day mean ADV of 834K, representing nearly 2× that average. In SIR terms, this is a textbook cluster_break_up: the scatter dot moves sharply up-and-right, with the volume expansion confirming that new demand — not thin-air drift — is absorbing the float at the breakout level. Risks: A single-session breakout bar, however powerful, is inherently vulnerable to failure if follow-through volume collapses in the next 2–3 sessions — a close back below $240 on above-average volume would signal a false break and invalidate the read. Additionally, the macro context flags an inflation-expectations print 1.9σ below trend (T5YIE 2.19 on 2026-08-04), which is not a primary tailwind for Health Care; a broad risk-off rotation or sector-specific earnings disappointment could cap the move before multi-session accumulation confirms.
- ?Jul 31, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down -1.55% today, which is a moderate but not aggressive intraday move. The move is below the 2-5% threshold that would itself constitute strong directional evidence. There are no recent headlines to explain the move or provide narrative momentum. The macro context (elevated mortgage rates) is not directly relevant to CRL's business (contract research/lab services), so no sector tailwind or headwind applies here. With 275 minutes remaining there is ample time for continuation, but also ample time for mean reversion. The absence of a clear catalyst makes it hard to assign high conviction to continuation — this looks more like routine selling or sector rotation rather than a news-driven flush. Slightly below 0.5 because the move lacks the magnitude and news backing that would suggest sustained institutional distribution, and there is no clear macro pressure on CRL specifically. Marginal fade lean.
- !Jul 31, 11:10 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down -1.55% today, which is a moderate but not aggressive intraday move. The move is below the 2-5% threshold that would itself constitute strong directional evidence. There are no recent headlines to explain the move or provide narrative momentum. The macro context (elevated mortgage rates) is not directly relevant to CRL's business (contract research/lab services), so no sector tailwind or headwind applies here. With 275 minutes remaining there is ample time for continuation, but also ample time for mean reversion. The absence of a clear catalyst makes it hard to assign high conviction to continuation — this looks more like routine selling or sector rotation rather than a news-driven flush. Slightly below 0.5 because the move lacks the magnitude and news backing that would suggest sustained institutional distribution, and there is no clear macro pressure on CRL specifically. Marginal fade lean.
- ?Jul 23, 12:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 3.34% today with no attributable headline, suggesting this is flow-driven — likely institutional repositioning or a catch-up move. The magnitude is meaningful and represents real conviction from whoever initiated. With 190 minutes remaining there is ample time for continuation or at least holding gains into the close. The macro context (T10Y2Y at 1.8σ below trend, slight bear-flattening flavor) is mildly negative for risk but CRL as a contract research organization is more defensive/healthcare-oriented and less directly exposed to yield curve dynamics than banks. No reversal signals are visible from the data provided — no fade described, no abnormal volume flags. The absence of news is not a disqualifier per framework. Overall this reads as ordinary momentum with no strong fade catalyst, warranting a modest continuation probability above 0.5 but not a high-conviction setup given the lack of a clear fundamental driver or sector tailwind to sustain the move.
- !Jul 23, 12:36 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
CRL is up 3.34% today with no attributable headline, suggesting this is flow-driven — likely institutional repositioning or a catch-up move. The magnitude is meaningful and represents real conviction from whoever initiated. With 190 minutes remaining there is ample time for continuation or at least holding gains into the close. The macro context (T10Y2Y at 1.8σ below trend, slight bear-flattening flavor) is mildly negative for risk but CRL as a contract research organization is more defensive/healthcare-oriented and less directly exposed to yield curve dynamics than banks. No reversal signals are visible from the data provided — no fade described, no abnormal volume flags. The absence of news is not a disqualifier per framework. Overall this reads as ordinary momentum with no strong fade catalyst, warranting a modest continuation probability above 0.5 but not a high-conviction setup given the lack of a clear fundamental driver or sector tailwind to sustain the move.
- ?Jul 20, 10:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down ~2% intraday with no attributable headline, suggesting the move is driven by either quiet institutional selling, sector rotation, or sympathy with broader defensive/CRO sector pressure. The macro context shows a T10Y2Y at 1.8σ below trend (flattish/slightly inverted), which is modestly supportive of defensive names like CRL — this creates a mild headwind to further downside continuation. However, with 335 minutes remaining (more than a full session's worth of trading time ahead of the 3:45 cutoff), there is ample runway for the move to persist if sellers remain in control. No news means no catalyst to reverse, but also no fresh catalyst to accelerate. The ~2% move is meaningful but sits at the lower bound of 'high conviction' flow. Overall, this is a borderline read: the macro context creates a slight fade bias for CRL specifically as a defensive name, but the existing momentum and time remaining argue for modest continuation. Calling it at the minimum threshold — no strong reason to reverse, but no strong reason to accelerate either.
- !Jul 20, 10:11 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down ~2% intraday with no attributable headline, suggesting the move is driven by either quiet institutional selling, sector rotation, or sympathy with broader defensive/CRO sector pressure. The macro context shows a T10Y2Y at 1.8σ below trend (flattish/slightly inverted), which is modestly supportive of defensive names like CRL — this creates a mild headwind to further downside continuation. However, with 335 minutes remaining (more than a full session's worth of trading time ahead of the 3:45 cutoff), there is ample runway for the move to persist if sellers remain in control. No news means no catalyst to reverse, but also no fresh catalyst to accelerate. The ~2% move is meaningful but sits at the lower bound of 'high conviction' flow. Overall, this is a borderline read: the macro context creates a slight fade bias for CRL specifically as a defensive name, but the existing momentum and time remaining argue for modest continuation. Calling it at the minimum threshold — no strong reason to reverse, but no strong reason to accelerate either.
- ?Jul 17, 10:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 1.54% today, which is a moderate but not outsized intraday move. There are no headlines to explain the move, suggesting it may be technical or flow-driven. The macro context shows 10-year inflation expectations (T10YIE) printing 1.6σ below trend, which is modestly supportive of long-duration assets and could provide a mild headwind to further equity selling in rate-sensitive sectors — though CRL (Charles River Laboratories) is a life sciences services company with moderate rate sensitivity. With 315 minutes remaining, there is ample time for the move to continue or reverse. The absence of news is not disqualifying, and the 1.54% decline represents real selling pressure. However, the move is not large enough to indicate strong institutional conviction, and the low inflation expectations reading slightly favors a risk-on/stabilization tone. Balancing these factors: mild downside momentum with no clear catalyst to accelerate it, moderate time remaining, and a neutral-to-slightly-opposing macro backdrop yields a borderline continuation probability. Defaulting to 0.5 per the system's framework for borderline reads.
- !Jul 17, 10:31 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 1.54% today, which is a moderate but not outsized intraday move. There are no headlines to explain the move, suggesting it may be technical or flow-driven. The macro context shows 10-year inflation expectations (T10YIE) printing 1.6σ below trend, which is modestly supportive of long-duration assets and could provide a mild headwind to further equity selling in rate-sensitive sectors — though CRL (Charles River Laboratories) is a life sciences services company with moderate rate sensitivity. With 315 minutes remaining, there is ample time for the move to continue or reverse. The absence of news is not disqualifying, and the 1.54% decline represents real selling pressure. However, the move is not large enough to indicate strong institutional conviction, and the low inflation expectations reading slightly favors a risk-on/stabilization tone. Balancing these factors: mild downside momentum with no clear catalyst to accelerate it, moderate time remaining, and a neutral-to-slightly-opposing macro backdrop yields a borderline continuation probability. Defaulting to 0.5 per the system's framework for borderline reads.
- ?Jul 13, 3:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down ~1.95% with only 30 minutes remaining until the forced close. The move is meaningful but sits just below the 2% threshold where conviction is clearest. With only 30 minutes left, there is very limited runway for the move to extend further to hit the +3% profit target — the stock would need to drop to roughly $224.50 from $228.87, requiring an additional ~2% move in a half-hour window. The macro context (T10Y2Y at 2.1σ below trend, a flattening/near-inverted curve) is modestly supportive of defensives, which could actually act as a mild headwind to further selling in a healthcare/CRO name like CRL. There are no catalysts or headlines amplifying the move, and with 30 minutes to close, late-session profit-taking by intraday sellers or mean-reversion buying from dip buyers is a real possibility. The tight time window is the dominant factor here — even a legitimate downside setup struggles to reach target in 30 minutes, making inaction the more disciplined call.
- !Jul 13, 3:15 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down ~1.95% with only 30 minutes remaining until the forced close. The move is meaningful but sits just below the 2% threshold where conviction is clearest. With only 30 minutes left, there is very limited runway for the move to extend further to hit the +3% profit target — the stock would need to drop to roughly $224.50 from $228.87, requiring an additional ~2% move in a half-hour window. The macro context (T10Y2Y at 2.1σ below trend, a flattening/near-inverted curve) is modestly supportive of defensives, which could actually act as a mild headwind to further selling in a healthcare/CRO name like CRL. There are no catalysts or headlines amplifying the move, and with 30 minutes to close, late-session profit-taking by intraday sellers or mean-reversion buying from dip buyers is a real possibility. The tight time window is the dominant factor here — even a legitimate downside setup struggles to reach target in 30 minutes, making inaction the more disciplined call.
- ?Jul 9, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[no_pattern] The SIR path tells a two-chapter story. Chapter one (Jun 24–Jul 2) was genuinely bullish: CRL broke out of its ~$182–$188 cluster on surging volume — Jun 24 at 937K (+8.31%), Jun 25 at 1.5M (+5.25%), and Jun 26 at 1.4M (+1.43%) — driving the scatter dot up-and-right in classic cluster_break_up fashion, ultimately reaching $230 on sustained 1.0–1.1M volume through Jul 1. Chapter two (Jul 2–Jul 8) immediately raised a caution flag: volume faded on each successive up-day (845K → 632K) while the two down-days of Jul 7–8 came on relatively firmer volume (806K, 741K), and price slid back to $223.96 — a tilt toward distribution on the scatter path. Today's Jul 9 bar (+4.30% to $233.60) is a new price high but was executed on only 517K shares — a volume z-score of -1.30, well below the 20-day ADV of 887K — meaning the dot moved sharply up the Y-axis without any rightward movement on the X-axis. Under SIR's framework, a price extreme reached on sub-average volume is not confirming accumulation; it is an unconfirmed single-bar event that cannot be classified as a clean cluster_break_up or accumulation without at least one follow-through session on expanding volume. Risks: A close back below $226–$228 (the Jul 6–7 consolidation zone) on rising volume would confirm distribution and invalidate any residual breakout thesis. Equally, if tomorrow's session cannot sustain $233+ on volume meaningfully above the 887K ADV, the Jul 9 bar must be treated as a low-conviction one-day spike with no SIR confirmation.
- ?Jul 9, 10:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 4.03% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects genuine conviction from a sizable participant. However, several factors temper enthusiasm: (1) No catalyst is identifiable, which raises the possibility this was a gap/open surge that has already largely played out. (2) The macro backdrop — T10Y2Y at 2.1σ below trend — is mildly curve-flattening, which benefits defensives/healthcare services names like CRL but doesn't provide strong incremental tailwind. (3) With 315 minutes remaining (over 5 hours), there is ample time for the move to either extend or mean-revert, but the lack of news makes a sustained grind higher less certain than a catalyst-driven move. (4) No reversal signals are noted. On balance, momentum alone is a mild positive — the move is real and large enough to suggest institutional buying — but without news or a strong sector catalyst, this sits at a modest continuation probability. The system's bounded risk profile (tight stop at -1.5%, +3% target) makes a lean toward continuation appropriate at the margin.
- !Jul 9, 10:31 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
CRL is up 4.03% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects genuine conviction from a sizable participant. However, several factors temper enthusiasm: (1) No catalyst is identifiable, which raises the possibility this was a gap/open surge that has already largely played out. (2) The macro backdrop — T10Y2Y at 2.1σ below trend — is mildly curve-flattening, which benefits defensives/healthcare services names like CRL but doesn't provide strong incremental tailwind. (3) With 315 minutes remaining (over 5 hours), there is ample time for the move to either extend or mean-revert, but the lack of news makes a sustained grind higher less certain than a catalyst-driven move. (4) No reversal signals are noted. On balance, momentum alone is a mild positive — the move is real and large enough to suggest institutional buying — but without news or a strong sector catalyst, this sits at a modest continuation probability. The system's bounded risk profile (tight stop at -1.5%, +3% target) makes a lean toward continuation appropriate at the margin.
- ?Jul 8, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 2.44% today with no attributable headline catalyst, suggesting the move is driven by institutional selling or sector rotation rather than a news event that could reverse. With 329 minutes remaining (a full session worth of time), there is ample runway for continuation if the selling pressure persists. The macro context shows a compressed T10Y2Y spread (2.0σ below trend), which is modestly supportive of defensives fading as bear-flattening dynamics typically pressure non-core defensives — CRL as a CRO/life sciences services name sits in a sector that can underperform in risk-off flattening environments. However, the absence of any news makes it difficult to identify a specific catalyst sustaining the move, and a 2.44% drop without headlines can attract dip buyers intraday. No clear reversal signal (no fade off highs back through key levels described) means momentum reads as intact. Overall, modest continuation bias with no strong confirming or disconfirming evidence — probability set just above the threshold.
- !Jul 8, 10:16 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is down 2.44% today with no attributable headline catalyst, suggesting the move is driven by institutional selling or sector rotation rather than a news event that could reverse. With 329 minutes remaining (a full session worth of time), there is ample runway for continuation if the selling pressure persists. The macro context shows a compressed T10Y2Y spread (2.0σ below trend), which is modestly supportive of defensives fading as bear-flattening dynamics typically pressure non-core defensives — CRL as a CRO/life sciences services name sits in a sector that can underperform in risk-off flattening environments. However, the absence of any news makes it difficult to identify a specific catalyst sustaining the move, and a 2.44% drop without headlines can attract dip buyers intraday. No clear reversal signal (no fade off highs back through key levels described) means momentum reads as intact. Overall, modest continuation bias with no strong confirming or disconfirming evidence — probability set just above the threshold.
- ?Jul 7, 3:26 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.86% with only 20 minutes remaining until the forced close. The move is meaningful and represents real flow, but the critical constraint here is time — with just 20 minutes left, there is very limited runway to reach the +3% profit target from current levels (which would require an additional ~0.14% move, actually achievable), but the risk/reward window is extremely compressed. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening signals) is modestly unfavorable for risk-on continuation, particularly in defensives-adjacent names like CRL (a contract research/lab services company). No supporting headlines to anchor the move as fundamental. With the position already up significantly intraday, late-session profit-taking and mean-reversion pressure are common. The combination of no news catalyst, adverse macro tone for the sector, and critically short time remaining tips the probability below 0.5 — the upside capture window is too narrow and end-of-day flattening by other participants is a real fade risk.
- !Jul 7, 3:26 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
CRL is up 2.86% with only 20 minutes remaining until the forced close. The move is meaningful and represents real flow, but the critical constraint here is time — with just 20 minutes left, there is very limited runway to reach the +3% profit target from current levels (which would require an additional ~0.14% move, actually achievable), but the risk/reward window is extremely compressed. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening signals) is modestly unfavorable for risk-on continuation, particularly in defensives-adjacent names like CRL (a contract research/lab services company). No supporting headlines to anchor the move as fundamental. With the position already up significantly intraday, late-session profit-taking and mean-reversion pressure are common. The combination of no news catalyst, adverse macro tone for the sector, and critically short time remaining tips the probability below 0.5 — the upside capture window is too narrow and end-of-day flattening by other participants is a real fade risk.
- !Jul 2, 6:03 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:45 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:31 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:16 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:04 PMsignal
options_momentum — insufficient_capital
- ?Jul 2, 10:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.31% today with no attributable headline, suggesting institutional flow rather than a news-driven spike that might be faded. With 300 minutes remaining (effectively a full afternoon session), there is meaningful time for continuation. The macro context shows T10YIE at 1.6σ below trend, indicating lower inflation expectations, which is modestly supportive for life science/CRO names like Charles River Labs that carry some long-duration growth characteristics. However, the absence of a clear catalyst introduces uncertainty about whether the move has exhausted its impetus — a 2.31% move is real but not extreme, and without volume data confirming conviction or a sector/news catalyst to sustain buying interest into the close, this is an ordinary momentum read rather than a high-conviction continuation setup. No reversal signals are apparent, so the default lean is mild continuation. Probability set at the lower end of the ordinary momentum range given the lack of corroborating evidence.
- ?Jun 25, 11:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.83% with 280 minutes remaining — ample time for continuation. The move is meaningful in magnitude, suggesting real institutional flow rather than noise. No headlines are present, which is neutral; absence of news does not disqualify momentum. The macro context shows T10YIE at 2.4σ below trend, indicating compressed inflation expectations and a low-rate environment. CRL (Charles River Laboratories) is a healthcare/biotech services name — not a classic long-duration play, so the macro tailwind is modest at best but not a headwind. With no reversal signals noted and time remaining substantial, the base case is mild continuation of momentum into the close. Probability is kept moderate (not high) because: (1) no catalyst is identifiable to sustain aggressive buying, (2) the move may already reflect most of the day's flow if it occurred early session, and (3) without volume confirmation data, conviction is limited. Overall, a slight lean toward continuation is justified given the asymmetric risk structure of the strategy.
- ?Jun 25, 9:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 4.76% today with no attributable headline, suggesting institutional flow or a catalyst not yet reflected in news (possibly analyst action, earnings revision, or sector rotation). The move is meaningful in magnitude and represents real conviction. Macro context shows T10YIE at 2.4σ below trend, indicating compressed inflation expectations and a risk-on, duration-friendly environment — modestly supportive for equities broadly. With 365 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for continuation. No reversal signals are evident from the data provided. However, without a clear news catalyst, the absence of a narrative anchor introduces uncertainty about sustained buying into the close, and a ~5% gap-up without news can sometimes attract profit-taking into the afternoon. On balance, the momentum bias slightly favors continuation given time remaining and macro tailwind, but confidence is modest.
- ?Jun 23, 11:21 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 1.54% today with no attributable headline catalyst, suggesting this is flow-driven rather than news-driven. The move is modest (below the 2-5% 'meaningful conviction' threshold), which limits how much weight to place on momentum alone. Macro context shows T10YIE at 1.7σ below its 24-month trend, indicating compressed inflation expectations — this is generally supportive for long-duration sensitive sectors and not a headwind for a CRO/life sciences name like Charles River Labs. With 265 minutes remaining there is ample time for continuation, which is a positive. However, the lack of a news catalyst, the subdued magnitude of the move, and no strong sector tailwind beyond benign rates leave this as a borderline setup. No reversal signal or fade pattern is evident, so the default lean is slight continuation. Probability set just above the 0.5 trigger threshold.
- ?Jun 23, 10:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up ~2% intraday with no attributable news headline, suggesting institutional flow or sector rotation is driving the move rather than a one-off catalyst. The macro context shows the 10Y inflation breakeven (T10YIE) is running 1.7σ below its 24-month trend, which is modestly supportive of long-duration and growth-sensitive names like CRL (a contract research/life sciences services company). Lower inflation expectations reduce discount rate pressure. With 335 minutes remaining (~5.5 hours), there is ample time for the move to extend or at minimum hold. No reversal signals are evident from the data provided. However, the move is only ~2%, not an extreme outlier, and absence of a catalyst headline limits conviction. Baseline momentum continuation probability applies — no strong reason to fade, but not a high-conviction setup either.
- ?Jun 22, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 2.50% with only 25 minutes until the forced close. The move is meaningful in magnitude but the extremely limited time remaining is the dominant constraint — there is simply not much runway left for continuation to express. No news catalyst is present to sustain selling pressure, and the macro context (low inflation expectations via T5YIE) is not directionally negative for CRL, a life sciences CRO name. With no headlines driving narrative momentum and the session nearly over, late-session profit-taking or mean reversion by short-term traders is at least as likely as continuation. The time factor alone pushes this below the 0.5 threshold.
- ?Jun 22, 11:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down ~1.89% today with no attributable headline catalyst, suggesting this is either sector rotation, quiet institutional selling, or sympathy with broader market pressure. The move is below the 2% threshold that would represent high-conviction flow, so it's meaningful but not definitively directional. Macro context shows 5Y inflation breakevens running 1.5σ below trend, which is mildly risk-supportive and could cap further downside in equities broadly — not a tailwind for continuation of this decline. With 255 minutes remaining (a full session effectively), there is ample time for the move to extend, but also ample time for a mean-reversion bounce if sellers are exhausted. No news eliminates a narrative catalyst but per guidance does not push below 0.5. On balance, the setup is borderline — mild downward momentum with no amplifying factors and a macro backdrop that is slightly counter to continuation. Assigning minimum threshold probability to capture the edge from the asymmetric stop/target structure.
- ?Jun 9, 10:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.45% today with no attributable news headline, suggesting this is either institutional flow or sector rotation rather than a headline-driven spike. With 310 minutes remaining (essentially the full second half of the session), there is ample time for momentum to continue into the close. The macro backdrop shows the T10Y2Y at 2.0σ below trend, which is mildly supportive for defensive/healthcare-adjacent names like Charles River Labs — a CRO/life sciences services company that tends to be relatively rate-insensitive and less exposed to the bank-sector concerns flagged by the flattening curve. There is no reversal signal or fade evident from the data provided. The absence of news is not a disqualifier per the framework; the move itself represents real flow. With no strong reason to expect a fade and meaningful time remaining, the base case is mild continuation or at least no reversal, putting the probability modestly above 0.5. The primary uncertainty is the lack of any catalyst context and the relatively modest move size that could easily consolidate rather than extend.
- ?Jun 8, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.00% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop. With 330 minutes remaining (essentially a full session still ahead), there is ample time for momentum to extend. The macro context shows a compressed yield curve (T10Y2Y at 0.38, 2.5σ below trend), which is modestly supportive of defensive/life sciences names like Charles River Labs as investors may rotate toward less rate-sensitive sectors. However, the absence of a clear catalyst and no confirming news keeps conviction moderate. The move is at the lower bound of the 2-5% 'meaningful' range, so momentum pressure exists but is not exceptional. No reversal signals or fade patterns are noted. Overall, a mild continuation bias is warranted — no strong reason to fade, but not enough conviction for a high-probability call.
- ?Jun 5, 9:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 3.29% intraday with no attributable headline, suggesting institutional flow or sector rotation driving the move. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) With 375 minutes remaining (over 6 hours), this is actually early-to-mid session, meaning there is ample time for both continuation and reversal — but also that the move may have already exhausted early momentum buyers. (2) No news catalyst means the move lacks a fundamental anchor that would draw in additional buyers into the close. (3) The macro context (T10Y2Y at 1.9σ below trend, flat/inverted yield curve) is mildly negative for risk-on sentiment and favors defensives/low-beta names — CRL as a contract research organization has some defensive characteristics but is not a pure beneficiary of this environment. (4) Absence of a clear catalyst raises the possibility this is a gap-and-fade setup rather than a sustained trend day. Overall, momentum is the primary positive signal; the setup is borderline with no strong reason to expect a reversal, so the probability edges just above 0.5 in favor of continuation.
- ?Jun 4, 2:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up ~2.95% today with no attributable headline, suggesting institutional flow or sector rotation driving the move. The absence of news is not a disqualifier — this magnitude of move reflects real conviction from someone with size. However, several factors temper enthusiasm: (1) The macro context shows T10Y2Y at 2.1σ below trend, a flattening/inverted curve environment that generally favors defensives but is mixed for CRL (a contract research/life sciences services name — not a pure defensive). (2) With 100 minutes remaining, there is adequate time for continuation but also meaningful time for a fade if the catalyst is not sustained. (3) No supportive news flow means we cannot confirm whether this is a durable catalyst or a technical squeeze/rotation trade. (4) CRL is already near the +3% profit target threshold, so upside from current levels toward that target is limited. On balance, momentum is modest-positive with no strong fade signal present, placing this in the ordinary continuation range. Taking the trade with the system's bounded risk parameters is justified, but conviction is not high.
- ?Jun 3, 10:37 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no recent news headlines or SEC filings available to explain the ~10.9% drop from the 30-day high, the decline appears more likely attributable to broader macro/sector rotation than company-specific deterioration. Charles River Laboratories (CRL) is a well-established CRO/preclinical services company, and absent negative catalysts, the underlying business is presumed financially sound. However, the macro backdrop — a yield curve (T10Y2Y at 0.42, 2σ below trend) signaling a flattening/risk-off environment — could weigh on growth-sensitive healthcare services names, limiting near-term upside catalysts.
- ?Jun 3, 10:36 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no recent news headlines or SEC filings available to explain the ~10.9% drop from the 30-day high, the decline appears more likely attributable to broader macro/sector rotation than company-specific deterioration. Charles River Laboratories (CRL) is a well-established CRO/preclinical services company, and absent negative catalysts, the underlying business is presumed financially sound. However, the macro backdrop — a yield curve (T10Y2Y at 0.42, 2σ below trend) signaling a flattening/risk-off environment — could weigh on growth-sensitive healthcare services names, limiting near-term upside catalysts.
- ?Jun 3, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is down 1.60% today with no attributable headlines, suggesting this is either technical selling, broad market pressure, or quiet institutional flow. The move is below the 2-5% threshold that would constitute strong conviction evidence on its own. Macro context shows the T10Y2Y spread at 2.0σ below trend, which is modestly favorable for defensives — CRL (Charles River Laboratories) operates in a defensive-leaning contract research niche, meaning the macro backdrop is mildly unsupportive of further downside. However, there is no reversal catalyst visible either. With 360 minutes remaining (a full session still ahead), there is ample time for continuation or reversal. The move is modest enough that it could easily be noise or light selling pressure that exhausts itself. No news, no clear sector catalyst, neutral-to-slightly-bullish macro for the name, and a sub-2% move argues for a borderline read. Assigning 0.50 — minimum threshold to take the trade per system rules — as there is no strong reason to expect a fade but equally no strong continuation signal.
- ?Jun 3, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.42 cash available; close=$174.79.
- ?Jun 3, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $5.86 cash available; close=$174.79.
- ?Jun 2, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $22.75 cash available; close=$174.71.
- ?Jun 2, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.58 cash available; close=$174.71.
- ?May 28, 9:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up ~4.95% today with no attributable headline, suggesting institutional flow or a catalyst not yet surfaced in news feeds. A move of this magnitude reflects genuine conviction from someone with size. However, several factors temper enthusiasm: (1) 380 minutes remaining is actually a full trading day's worth — today is likely early session, meaning the move has already run and there is significant time for profit-taking and mean reversion; (2) macro context shows T10Y3M at 1.8σ above trend, which is mildly risk-on for equities broadly but CRL (Charles River Laboratories) is a life sciences CRO — not a primary beneficiary of yield curve steepening, and could face headwinds if recession-sensitive sentiment builds; (3) no news to sustain narrative momentum increases fade risk as the day progresses; (4) a ~5% gap/run without a clear catalyst is susceptible to late-session giveback as early buyers trim. On balance, the base momentum case supports slight continuation, but there is no strong accelerant. Probability sits just above the threshold, reflecting ordinary momentum with no strong reason to reverse but no clear fuel for further extension.
- ?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$164.49.
- ?May 28, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $8.03 cash available; close=$164.49.
- ?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$164.49.
- ?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings available to explain the 15.5% drop from CRL's 30-day high, suggesting the move may be driven by macro or sector-rotation forces rather than company-specific deterioration. Charles River Laboratories (CRL) is an established CRO/preclinical services company with a historically solid balance sheet, though the sector has faced headwinds from biotech funding cycles and drug development outsourcing trends. The macro context shows a steepening yield curve (T10Y3M at 1.9σ above trend), which tends to pressure growth-oriented and recession-sensitive sectors, and CRL's revenue is partly tied to biotech client spending cycles that can be sensitive to credit conditions.
- ▣May 19, 8:00 PMjournalstop
options_momentum closed long 100 @ $10.97 (+$91.83)
Stop: premium $10.97 ≤ trailing floor $11.18 (peak $14.90 × 0.75)
- ❖May 17, 5:24 AMnewsvia finnhub
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.
- ❖May 16, 2:34 AMnewsvia finnhub
What Moved Markets This Week
U.S. stocks ended the week mostly unchanged amid persistent inflation pressures and surging Treasury yields. Read more about this week's major events on Wall Street.
- ▢May 13, 8:00 PMjournal
options_momentum opened long 100 @ $10.05